CAR-T (Heme) vs CAR-T (Solid Tumor) — Oncology Deal Terms Comparison
Market Analysis
In oncology, CAR-T (Heme) and CAR-T (Solid Tumor) represent two of the most actively transacted modalities. At Phase 2, CAR-T (Heme) deals carry a median total deal value of $2.0B with $309M upfront, compared to $2.3B total value and $356M upfront for CAR-T (Solid Tumor). The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. CAR-T (Heme) development milestones average $414M versus $484M for CAR-T (Solid Tumor). Commercial milestones are $580M for CAR-T (Heme) and $678M for CAR-T (Solid Tumor). Royalty rates range from 12.5%-20.4% for CAR-T (Heme) and 13%-21.3% for CAR-T (Solid Tumor).
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do CAR-T (Heme) and CAR-T (Solid Tumor) deal terms compare in oncology?
Which modality commands higher royalty rates: CAR-T (Heme) or CAR-T (Solid Tumor)?
How do milestone structures differ between CAR-T (Heme) and CAR-T (Solid Tumor)?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.